Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Oct 2 - Oct 7
#Semaglutide I #Patent_cliff I #Market I #generics I #global_scale I #India I Systematix Group Read more: To view or add a comment, sign in Analysis: The loss of #Semaglutide patents is a major strategic turning point for #IndianPharma, unlocking an estimated 5,000 crore (~$600M) #GenericOpportunity across #India and regulated #EmergingMarkets like #Canada and #Brazil as exclusivity ends
Larsen et al
We identified a T2DM cohort of 294,148 participants from the Korean NHIS database from 2009 to 2018 (Fig
The Union Budget 2026-2027 is transforming India into a global biopharma hub
In recent years, weight loss medicines have become a major trend
Selective melanocortin-1 receptor (MC1R) agonist investigated
US$ 24.17
US$ 23.12
US$ 22.28
US$ 28.35
US$ 25.60
US$ 25.68
